Rivas Goldstein, LLP Call : 512-481-8000

Drug maker agrees to settle kickback allegations for $210 million

United Therapeutics Corporation (UT), based in Maryland, has just agreed to settle Anti-Kickback Statute and False Claims Act allegations for $210 million. The drug maker has also entered into a five-year corporate integrity agreement with the Department of Health and Human Services Office of Inspector General.

The allegations involve copayments, coinsurance and deductibles ("copays") for several of UT's pulmonary arterial hypertension drugs, Adcirca, Remodulin, Tyvaso, and Orenitram. According to the Department of Justice, UT overcame the Anti-Kickback Statute's prohibition on pharmaceutical companies' payment of patient copays by essentially directing its foundation to make the payments.

Between 2010 and 2014, the DOJ says, UT made donations to the foundation which were used to pay copays for the PAH medications. The foundation turned over data about these payments to UT, which in turn used that data to determine how much to donate to the foundation. The DOJ argues that this was done in an effort to induce patients to take UT medications.

"UT used a third party to do exactly what it knew it could not lawfully do itself," said an acting U.S. attorney.

In addition, the government alleges that UT had a policy that adversely affected Medicare patients and cost Medicare money. The company had a program that provided free drugs to needy patients, but UT's policy was not to accept Medicare patients in that program. Instead, Medicare patients were referred to the foundation for copay assistance and claims were submitted to Medicare. This, the DOJ argues, violated the False Claims Act.

A large number of state and federal agencies participated in the investigation into UT:

  • The Justice Department's Civil Division
  • The U.S. Attorney's Office for the District of Massachusetts
  • The Department of Health and Human Services, Office of Inspector General
  • The Federal Bureau of Investigation
  • The Department of Veterans Affairs, Office of Inspector General
  • The United States Postal Inspection Service

The imbalance in power between the government and the drug maker is notable. With multiple agencies using their full investigative authority, the pressure to pay a fine and enter into a corporate integrity agreement would have been substantial.

If your health care company is under investigation for violations of the Anti-Kickback Statute, the Stark Act, or any regulation, the time to obtain counsel is now. The earlier in the process your attorneys become involved, the better their chance of protecting you from serious consequences.

No Comments

Leave a comment
Comment Information
Email Us For A Response

Rivas Goldstein LLP: On Your Side, Protecting Your Future

Our experienced Texas-based health care lawyers are here to help you and your business succeed. Please call 512-481-8000 or contact our law firm online.

Schedule A Consultation With An Attorney

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy

Austin Office
7035 Bee Cave Road, Suite 200
Austin, TX 78746

Phone: 512-481-8000
Fax: 512-481-0022
Austin Law Office Map

New York Office
405 Lexington Ave 26th Floor
New York, NY 10174

Phone: 212-541-2451
Fax: 917-368-8005
Map & Directions

McAllen Office
1100 East Jasmine Ave
Suite 105
McAllen, TX 78501

Phone: 512-481-8000
Map & Directions

Review Us